Hemas Holdings Ltd.

HHL.N0000Moderately undervalued

Diversified Holdings · Industrial Conglomerates

Hemas Holdings PLC is a diversified Sri Lankan conglomerate with principal activities across consumer goods, healthcare, mobility, leisure, travel and aviation, and logistics and maritime services.

HHL shares are down 6.1% over the past year and last closed at Rs 31.00 on Sep 30, 2026.

Rs 31.00
+1.31%
Price history
-6.06%

Monthly seasonality

Monthly total returns by year and calendar month
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026+0.3-2.3-12.4+11.1-2.7+3.1-3.0-0.9-2.2+0.0+0.0+0.0
2025+10.7+3.7+1.3+1.2+15.2+8.9+1.0-1.3+7.6+6.1+3.2-3.6
2024+0.1+8.0+7.8+10.0-1.5-4.0-5.4-5.7+4.8+6.9+1.7+21.6
2023+5.0+8.0+2.0-2.8+0.5+9.4+10.5+5.5-1.9-10.2-0.6-3.0
2022+4.9-8.7-29.6-7.6+8.2-2.2+5.7+22.6+11.4-13.4+1.8+0.4
2021-3.1-16.4+1.9-3.0-0.1+2.5-3.5-7.6-2.7+3.2-6.5-2.6
2020-10.2-6.7-15.1+0.0+0.0+2.4-6.0+0.5+25.0-7.6+27.0+13.6
2019-4.5-4.7-4.0-4.0-5.6-8.8+25.0-3.2+0.0+6.8+3.0+0.6
2018-4.8+4.3+0.0+0.0-0.8-9.6-10.8-8.0-7.1-0.6+4.7+0.0
2017+2.0+6.9+1.7+7.5+3.8+25.6-4.5-11.6-8.4+9.2-3.8+0.8
2016-8.5-6.0+0.1+13.7-0.1-5.4+4.0+7.4+8.3+2.9-11.2+4.2
2015+10.4-2.6-6.8+2.6+5.4+1.9+7.4-0.1-3.4-2.9+3.0+9.3
2014+23.5-8.3-2.1+12.5-3.3+6.8+12.1+3.9+19.6+14.8-2.9+9.3
2013+3.7-5.0+1.5+6.7+28.1-6.5-4.9-8.5+6.7+1.6+2.2+2.4
2012+0.0+0.0+0.0-8.4-12.4+4.7+0.0+11.8+23.5-8.2-3.6+0.0
Average+2.1-2.1-3.8+2.8+2.5+1.9+1.8+0.3+5.4+0.6+1.3+3.8
ASPI average+3.1-2.7-4.7+2.0+0.2+0.8+3.1+2.2+3.2-0.1+1.0+3.0
Median+1.2-3.6+0.1+1.9-0.1+2.4+0.0-0.9+4.8+2.2+1.7+0.7
% up64%36%50%57%43%60%47%40%53%57%57%64%
P/E
10.7
P/B
1.66
EPS
Rs 2.89
Div Yield
3.23%
Market Cap
Rs 92.9B
Beta
0.69
ROE
15.5%
Op Margin
5.7% (-1.6pp)

Fundamentals

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue
Rs 127.4B
+8.0%
Rs 118.0B
-3.0%
Rs 121.6B
+6.7%
Rs 113.9B
+44.5%
Rs 78.8B
+22.2%
Rs 64.5B
+4.7%
Rs 61.6B
-3.8%
Rs 64.1B
+26.0%
Operating profit
Rs 14.1B
+3.2%
Rs 13.7B
+15.0%
Rs 11.9B
+8.7%
Rs 11.0B
+61.6%
Rs 6.8B
+11.9%
Rs 6.1B
+70.2%
Rs 3.6B
-37.1%
Rs 5.7B
+33.4%
Net profit
Rs 9.3B
+11.4%
Rs 8.3B
+31.2%
Rs 6.4B
+25.4%
Rs 5.1B
+4.8%
Rs 4.8B
+44.7%
Rs 3.3B
+145.3%
Rs 1.4B
-63.0%
Rs 3.7B
+24.7%
EPS
2.98
+10.4%
2.70
-73.6%
10.24
+43.0%
7.16
+0.6%
7.12
+30.4%
5.46
+163.8%
2.07
-63.4%
5.65
+20.7%

Compared with the same period a year earlier.

Per-share figures are as reported, not adjusted for splits.

Recent dividends

  • 2026 · finalRs 0.75
  • 2026 · first interimRs 0.25
  • 2025 · finalRs 0.70
  • 2025 · first interimRs 1.00
  • 2024 · finalRs 3.00
  • 2024 · first interimRs 0.40
  • 2023 · finalRs 1.95
  • 2023 · first interimRs 0.40
Peer comparison7 peers in Diversified Holdings
Rs 18.70
P/E
22.7
P/B
0.80
ROE
3.49%
Yield
1.60%
MELS.N0000
Rs 185.00
P/E
10.7
P/B
1.29
ROE
12.13%
Yield
4.41%
HAYL.N0000
Rs 225.50
P/E
12.1
P/B
1.52
ROE
13.67%
Yield
2.66%
Rs 720.00
P/E
15.5
P/B
1.29
ROE
8.68%
Yield
1.76%
CTHR.N0000
Rs 540.00
P/E
13.9
P/B
2.91
ROE
20.99%
Yield
2.82%
VONE.N0000
Rs 88.80
P/E
7.2
P/B
0.81
ROE
11.20%
Yield
1.69%
HHL.N0000 · this company
Rs 31.00
P/E
10.7
P/B
1.66
ROE
15.53%
Yield
3.23%
BUKI.N0000
Rs 846.00
P/E
19.4
P/B
1.09
ROE
6.34%
Yield
2.38%
Peer median · 7 companies
P/E 13.9P/B 1.29Yield 2.38%

About Hemas Holdings Ltd.

Hemas Holdings PLC is a diversified Sri Lankan conglomerate with principal activities across consumer goods, healthcare, mobility, leisure, travel and aviation, and logistics and maritime services. The Group markets home and personal care and other consumer products domestically and in regional markets, and has a portfolio of businesses across pharmaceuticals, hospitals, hospitality and travel. The Healthcare vertical comprises pharmaceutical distribution and manufacturing (Morison), and a hospitals group operating facilities such as Wattala and Thalawathugoda; the Consumer vertical includes home and personal care categories and brands such as Atlas (including a 'Back to School' range). The Group also operates hotels and inbound travel businesses including Serendib Hotels (SHOT) and Anantara Peace Haven Tangalle, and maintains operations in Sri Lanka with regional presence in Bangladesh, West Bengal and Myanmar. Hemas positions itself as a national leader in consumer and healthcare solutions, seeking to develop brands, commercial partnerships and manufacturing capacity while engaging in route-to-market and regulatory initiatives relevant to its sectors.

AI analysis

bullish

Evidence points bullish: earnings grew in FY2026 and Hemas has a net-cash balance sheet, supporting a moderately undervalued rating. The June quarter's profit fell 15.7% as margins compressed.

Read the full report (Sep 24, 2026) →

News sentiment

Describes news flow, not a forecast
Last 30 days
More negative than usual for this company
its own lowits own high

Higher than 0% of its last 19 months · 5 of 9 in its sector

6 articles in 30 days: 1 positive, 4 negative, 1 neutral.

24 months positive negative 3-month net
Oct 24: 3 articles, net +0.33Nov 24: 7 articles, net +0.81Jan 25: 5 articles, net +0.20Feb 25: 3 articles, net +0.33Mar 25: 6 articles, net -0.13Apr 25: 5 articles, net +0.71May 25: 7 articles, net +1.00Jun 25: 4 articles, net +1.00Jul 25: 2 articles, net +0.17Aug 25: 3 articles, net +0.82Sep 25: 3 articles, net +0.71Oct 25: 3 articles, net +1.00Nov 25: 7 articles, net +0.10Dec 25: 7 articles, net +0.00Jan 26: 7 articles, net +0.74Feb 26: 2 articles, net +1.00Mar 26: 3 articles, net -0.20Apr 26: 1 articles, net +1.00May 26: 13 articles, net +0.38Jul 26: 4 articles, net +0.67Aug 26: 8 articles, net +0.31Sep 26: 6 articles, net -0.43Oct 24Feb 25Jun 25Oct 25Feb 26Jun 26
Recent news
View all news →
Ada Derana·Sep 28, 2026·Promotional / marketing
SLEIS 2026 to Explore New Opportunities in Sri Lanka's Health Economy

SLEIS 2026 will examine Sri Lanka's Health Economy at a summit on 12-13 October 2026, with the session 'Reimagining Healthcare for a Modern Health Economy' featuring executives from Hemas and Sunshine and moderated by Sunshine's CEO; sponsors include Dialog and Hayleys. Registrations are open.

Healthcare & Pharma
EconomyNext·Sep 28, 2026·Promotional / marketing
Sri Lanka investor forum to explore opportunities in health

The Sri Lanka Economic & Investment Summit 2026 will feature a session 'Reimagining Healthcare for a Modern Health Economy' on Oct 12-13 to explore private-sector investment and opportunities across healthcare services, pharmaceuticals and medical technology. Panelists include Hemas Holdings (HHL.N0000) and Sunshine Holdings (SUN.N0000).

Healthcare & Pharma
EconomyNext·Sep 28, 2026·Market commentaryNegative
Sri Lanka stocks trend up; ASPI passes 21,000

Colombo Stock Exchange opened higher as the ASPI rose 30.69 points to 21,068.04 (up 0.15%); market turnover was 57.56 million rupees. Vidullanka said project companies it holds equity in won bids to install 18.7 MW/93 MWh of BESS, with its estimated equity share about 600 million rupees.

Renewable Energy
EconomyNext·Sep 25, 2026·Market commentaryNegative
Sri Lanka stocks open up, ASPI gains 0.18-pct

Colombo Stock Exchange opened higher: ASPI up 0.18% (37.48 pts) at 21,104.37 and S&P SL20 up 0.46% at 5,970.10, with turnover Rs 43.59m. Singer Finance set rights-issue and EGM/XR dates; Pan Asia Banking plans to raise up to Rs 5bn via listed debentures opening Oct 1, 2026.

EconomyNext·Sep 24, 2026·Credit rating action
Fitch affirms Sri Lanka's Ceat Kelani at 'AA+(lka)'; Outlook Stable

Fitch affirmed Ceat Kelani Holdings' National Long-Term Rating at 'AA+(lka)' with a Stable Outlook. Fitch highlighted CKH's market leadership and resilient finances but warned of near-term margin pressure from higher input and energy costs and import competition, with EBITDA net leverage seen peaking around 0.6x in FY28.

Ada Derana·Sep 24, 2026·Promotional / marketingPositive
Kalasuri Channa Wijewardena is Diabetasol's Brand Ambassador

Diabetasol named Kalasuri Channa Wijewardena as brand ambassador for its 'Keep Life in Rhythm' campaign to promote specialised nutrition for people with diabetes. The product is marketed locally by Hemas Pharmaceuticals in partnership with Kalbe.

Consumer Staples (FMCG)Healthcare & Pharma
Ada Derana·Sep 21, 2026·Promotional / marketingPositive
Baby Cheramy Partners with Sri Lanka College of Paediatricians at the 19th Asia Pacific Congress of Paediatrics: Redefining Paediatric Care – Blending Equity, Excellence and Technology

Hemas Holdings' Baby Cheramy partnered with the Sri Lanka College of Paediatricians at the 19th Asia Pacific Congress of Paediatrics and showcased its relaunched multi‑benefit baby care range. The products are dermatologically/clinically tested and marketed as baby‑safe, with new formulations (Natural Ceramides) and diaper/pants options.

Consumer Staples (FMCG)
EconomyNext·Sep 11, 2026·Market commentaryNegative
Sri Lanka stocks reverse morning losses to close up

Colombo Stock Exchange closed higher with the ASPI up 0.12% (25.00 pts) at 21,382.74 and the S&P SL20 up 0.19% at 6,015.08, on turnover of 333 million rupees. Galle Face Capital Partners received in-principle CSE approval to list up to 4,060,218 new ordinary shares via a scrip dividend; its shares closed down 2.45% at 19.90 rupees.

EconomyNext·Sep 9, 2026·Market commentaryPositive
Stocks close down on Wednesday, capital goods lead turnover

Colombo Stock Exchange closed down as the ASPI fell 0.25% (down 53.01 pts) to 21,489.22 on Wednesday, with market turnover at LKR 972.23 mn and capital goods leading turnover at LKR 283.19 mn. HNB Finance appointed four new independent/non-executive directors effective Sept 8, 2026; its shares closed down 1.20% at 8.20 rupees.

EconomyNext·Sep 2, 2026·Market commentaryNegative
Sri Lanka stocks close flat on Rs1.28bn turnover

Colombo Stock Exchange closed marginally up, ASPI +0.03% at 21,325.64 on Rs1.28bn turnover; banks led turnover. Top contributors included Ceylinco Insurance, Haycarb, Dipped Products and National Development Bank, while Browns Investments, Carson Cumberbatch, Melstacorp and Hemas were laggards; Hunas announced a strategic partnership with Tokyo-based CCH Inc.